Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2008

View Archived Issues

Labopharm reports positive results for phase III trazodone study

e-STAR data show risperidone long-acting injection beneficial in schizophrenia

Add-on pimavanserin improves efficacy and safety of risperidone in schizophrenia

Cervical cancer vaccine safe, immunogenic in stage IB and IIA patients

Pro-Pharmaceuticals reports encouraging data from phase II trial of Davanat in colorectal cancer

Blood pressure control safely achieved with clevidipine in high risk patients

AstraZeneca submits application for Seroquel and Seroquel XR in the E.U.

Keryx Biopharmaceuticals completes phase III clinical trial of Sulonex

La Jolla Pharmaceutical presents an update on the phase III trial of Riquent for SLE

Recent patents impart novel treatment options for cancer

Washington University investigators study role of moss protein in Alzheimer's disease

Targanta submits NDA to FDA for oritavancin

Preliminary clinical data show significant HIV viral load reduction with IDX-899

Silodosin NDA accepted for filing by FDA for benign prostatic hyperplasia

Biovitrum completes exploratory phase II study of BVT-28949 in glaucoma

Positive efficacy data reported from phase II Gabapentin GR trial

SCH-532706 safe and well tolerated in combination with ritonavir

Valeant reports positive phase III results for retigabine in RESTORE 1

Decapeptyl 6-month formulation shows similar efficacy to 3-month triptorelin

Study shows self-applied diarrhea vaccine patch has robust immune response

Recent Merck patents describe novel agents for sleep disorders

Recent Allergan patents disclose new therapeutics for glaucoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...